Amoxicillin

Generic Name: Amoxicillin

Brand Names: Amoxil, Augmentin, Clavulin, Moxatag, Omeclamox, Prevpac, Talicia, Voquezna 14 Day Dualpak 20;500, Voquezna 14 Day Triplepak 20;500;500

Drug Type: Small Molecule

Chemical Formula: C_₁₆H_₁₉N_₃O_₅S

CAS Number: 26787-78-0

Unique Ingredient Identifier: 9EM05410Q9

Background: Amoxicillin, or BRL-2333, is a penicillin G derivative first described in the literature in 1972. Amoxicillin has similar activity to penicillin and ampicillin, but leads to higher serum concentrations than ampicillin.

Amoxicillin was granted FDA approval on 18 January 1974.

Indication: Amoxicillin alone is indicated to treat susceptible bacterial infections of the ear, nose, throat, genitourinary tract, skin, skin structure, and lower respiratory tract. Amoxicillin is given with calvulanic acid to treat acute bacterial sinusitis, community acquired pneumonia, lower respiratory tract infections, acute bacterial otitis media, skin and skin structure infections, and urinary tract infections. Amoxicillin is given with omeprazole in the treatment of Helicobacter pylori (H. pylori) infection.

Amoxicillin is used in combination with vonoprazan and clarithromycin as co-packaged triple therapy or in combination with vonoprazan as co-packaged dual therapy to treat H. pylori infection in adults.

Associated Conditions: Acute Bacterial Sinusitis (ABS), Acute Otitis Media (AOM), Bacterial Infections, Community Acquired Pneumonia (CAP), Duodenal ulcer caused by helicobacter pylori, Genitourinary tract infection, Helicobacter Pylori Infection, Lower Respiratory Tract Infection (LRTI), Peptic Ulcer With H. Pylori Infection, Sinusitis, Skin and Subcutaneous Tissue Bacterial Infections, Urinary Tract Infection, Acute, uncomplicated Gonorrhea, Ear, nose, and throat infections

Associated Therapies: -

Clinical Trials

Amoxicillin/Metronidazole Based Quadruple Therapy for Helicobacter Pylori Eradication

Phase 4

Completed

Conditions: Peptic Ulcer
Dyspepsia

Interventions: Drug: Lansoprazole
Drug: Bismuth Potassium Citrate
Drug: Amoxicillin
Drug: Metronidazole
Drug: Clarithromycin

First Posted Date: 2014-06-26

Last Posted Date: 2015-02-03

Lead Sponsor: Shanghai Jiao Tong University School of Medicine

Target Recruit Count: 215

Registration Number: NCT02175901

Locations: 🇨🇳
Shanghai Renji Hospital, Shanghai Jiao-Tong University School of Medicine, Shanghai, Shanghai, China

Compare Sequential and Quadruple Therapy for the Eradication of Helicobacter Pylori in Korea

Not Applicable

Completed

Conditions: Helicobacter Pylori Infection

Interventions: Drug: Pantoprazole
Drug: Amoxicillin
Drug: Clarithromycin
Drug: Tetracycline
Drug: Bismuth
Drug: Metronidazole

First Posted Date: 2014-06-10

Last Posted Date: 2019-05-13

Lead Sponsor: Seoul National University Bundang Hospital

Target Recruit Count: 390

Registration Number: NCT02159976

Locations: 🇰🇷
Seoul National University Bundang Hospital, Seongnam-si, Gyeonggi-do, Korea, Republic of

Necessity of Antibiotics for Prevention of Delivery-associated Infections After Spontaneous Vaginal Delivery at Term

Phase 4

Terminated

Conditions: Perineal Wound Infection

Interventions: Drug: Placebo
Drug: Amoxicillin

First Posted Date: 2014-05-06

Last Posted Date: 2015-12-03

Lead Sponsor: Mahidol University

Target Recruit Count: 5

Registration Number: NCT02131818

Locations: 🇹🇭
Faculty of Medicine Siriraj Hoapital Mahidol University, Bangkok, Thailand

A New Antibiotic Prophylaxis Regimen to Prevent Bacteremia Following Dental Procedures

Not Applicable

Completed

Conditions: Bacteremia

Interventions: Drug: Amoxicillin-Potassium Clavulanate
Drug: Amoxicillin
Drug: Chlorhexidine

First Posted Date: 2014-04-16

Last Posted Date: 2015-05-27

Lead Sponsor: University of Santiago de Compostela

Target Recruit Count: 266

Registration Number: NCT02115776

Locations: 🇪🇸
Santiago de Compostela University Hospital, Santiago de Compostela, Coruña, Spain
🇪🇸
Hospital Clinico Universitario de Santiago, Santiago de Compostela, A Coruña, Spain

Pilot Study of PUFA-optimized RUTF for Severe Acute Malnutrition

Not Applicable

Completed

Conditions: Kwashiorkor
Marasmus

Interventions: Dietary Supplement: RUTF
Dietary Supplement: RUTF-P
Drug: Amoxicillin

First Posted Date: 2014-02-04

Last Posted Date: 2014-09-29

Lead Sponsor: Washington University School of Medicine

Target Recruit Count: 141

Registration Number: NCT02053857

Locations: 🇲🇼
University of Malawi College of Medicine, Blantyre, Malawi

Treatment of Antenatal Chlamydia Infection

Phase 2

Completed

Conditions: Chlamydia Trachomatis Infection in Pregnancy

Interventions: Drug: Amoxicillin
Drug: Erythromycin

First Posted Date: 2013-09-19

Last Posted Date: 2014-03-27

Lead Sponsor: Obafemi Awolowo University Teaching Hospital

Target Recruit Count: 220

Registration Number: NCT01946256

Locations: 🇳🇬
Obafemi Awolowo University Teaching Hospitals Complex, Ile Ife, Ile Ife, Imesi Ile, Nigeria

Bioequivalence of Two Commercial Amoxicillin Suspensions

Phase 4

Completed

Conditions: Bioequivalence of Amoxicillin

Interventions: Drug: amoxicillin

First Posted Date: 2013-09-02

Last Posted Date: 2013-09-02

Lead Sponsor: University of Campinas, Brazil

Target Recruit Count: 25

Registration Number: NCT01933698

Locations: 🇧🇷
BIOAGRI Laboratórios Ltda, Piracicaba, SP, Brazil

Non-antibiotic Prescribing for Acute Upper Respiratory Tract Infection

Not Applicable

Withdrawn

Conditions: Acute Upper Respiratory Tract Infection

Interventions: Drug: Amoxicillin

First Posted Date: 2013-08-29

Last Posted Date: 2023-05-01

Lead Sponsor: Daping Hospital and the Research Institute of Surgery of the Third Military Medical University

Registration Number: NCT01930955

Locations: 🇨🇳
Department of Pediatrics, Daping Hospital, Research Institute of Surgery, Third Military Medical University, Chongqing, Chongqing, China